Full Year 2024 Oxford Biomedica PLC Earnings Call Transcript
Key Points
- Oxford BioMedica PLC (OXBDF) achieved an impressive organic revenue growth of 81% in 2024, with total revenues increasing by 44% to GBP128.8 million.
- The company reported a significant improvement in operating EBITDA, narrowing the loss from GBP52.8 million in 2023 to GBP15.3 million in 2024, and achieving a GBP5 million operating EBITDA profit in the second half of 2024.
- Oxford BioMedica PLC (OXBDF) expanded its operational footprint by acquiring a site in France, enhancing its ability to meet growing demand across Europe.
- The company launched the inAAVate platform for better AAV production, which is expected to enhance vector yield and quality.
- Oxford BioMedica PLC (OXBDF) has a strong commercial momentum with contracted client orders reaching GBP186 million in 2024, a 35% increase from the previous year.
- Despite the revenue growth, Oxford BioMedica PLC (OXBDF) still reported an operating EBITDA loss of GBP15.3 million for 2024.
- The company faces potential challenges from US tariffs, which could impact costs and supply chains, although the exact impact remains uncertain.
- There is a risk of delays in early-stage activities due to potential difficulties in accessing funds, which could affect the pipeline.
- The company has a significant exposure to FX fluctuations, with revenues receivable in multiple currencies, which could impact financial performance.
- Oxford BioMedica PLC (OXBDF) postponed investment in Oxbox manufacturing capacity, indicating potential constraints in expanding production capabilities in the short term.
So good afternoon to everyone here in London and also good morning to those who are joining us from overseas. Thank you for attending this call today, our analyst briefing for our '24 preliminary results. It's great to see so many people here in the room, known faces, thank you for joining.
But we have also a few people joining virtually. So hello to everyone again. Presenting with me today, we have our Chief Financial Officer, Dr. Lucy Crabtree, who started to join us in September last year and has already made a significant impact during this short period. I'm also pleased to welcome our Chief Business Officer, Dr. Sébastien Ribault. You are known, I believe, well here and a lot of you are familiar with him.
So disclaimer, let's -- before we dive in, let's start with our agenda for today. As you can see, we will start with an overview of the key achievements across the business, highlighting what sets up OXB apart from our peers and how our differentiated pure play CDMO strategy and cell gene therapy
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
